Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…
How Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement.
It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then, our team has been hard…
Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.
The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment.
The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.
Cytonics aims to address osteoarthritis, impacting over 500 million globally, with its innovative CYT-108 therapy. Positioned strategically in capital markets, the company targets Phase 2-ready investments. With strong intellectual property and funding strategies, Cytonics is well-prepared for M&A opportunities, benefiting from current biotech trends and investor interests.
Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.
Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.
As 2024 ends, Cytonics reflects on remarkable progress in developing their drug CYT-108 for osteoarthritis treatment. The first clinical trial began, greatly aided by a team of orthopedic specialists. Plans for Phase 2 trials are underway, with fundraising efforts expected in early 2025 to support research and development.
